A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington’s Disease

Condition: Early Manifest Huntington Disease
Interventions: Drug: Branaplam; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting

Author:

Published July 16, 2022

Categorized as Clinical Trials

Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD

Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis

About the blog

Health Information Technology System News and Healthcare Advances. Also Learn More about the Field of Health Data Scientists

Please leave this field empty

Health Data Scientist

Don’t miss these tips!

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

New Product Review

Evaluate New Health Applications. Be the first to decide. Your opinion matters.

Survey